Do analysts prefer MEDP or BIO.B?

Medpace currently has a consensus price target of $595.20, suggesting a potential downside of 3.83%. Given Medpace's stronger consensus rating and higher possible upside, research analysts plainly believe Medpace is more favorable than Bio-Rad Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medpace 0 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 Bio-Rad Laboratories 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, MEDP or BIO.B?

Bio-Rad Laboratories has higher revenue and earnings than Medpace. Medpace is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.83 $451.12M $17.06 36.28 Bio-Rad Laboratories $2.58B 3.78 $759.90M $8.25 44.25

Do analysts prefer BIO.B or RVTY?

Revvity has a consensus target price of $116.57, suggesting a potential downside of 22.72%. Given Revvity's stronger consensus rating and higher probable upside, analysts clearly believe Revvity is more favorable than Bio-Rad Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Rad Laboratories 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Revvity 0 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22

Do analysts prefer BIO.B or ICLR?

Icon has a consensus target price of $170.07, suggesting a potential downside of 1.31%. Given Icon's stronger consensus rating and higher possible upside, analysts plainly believe Icon is more favorable than Bio-Rad Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Rad Laboratories 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Icon 2 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.41

Bio-Rad Laboratories (BIO.B) Competitors

$365.08 0.00 (0.00%)

As of 09/25/2026

Compare

BIO.B vs. MTD, MEDP, RVTY, CRL, and ICLR

Should you buy Bio-Rad Laboratories stock or one of its competitors? Bio-Rad Laboratories's main competitors and comparable companies include Mettler-Toledo International (MTD), Medpace (MEDP), Revvity (RVTY), Charles River Laboratories International (CRL), and Icon (ICLR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Bio-Rad Laboratories compare to Mettler-Toledo International?

Mettler-Toledo International (NYSE:MTD) and Bio-Rad Laboratories (NYSE:BIO.B) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Mettler-Toledo International has higher revenue and earnings than Bio-Rad Laboratories. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mettler-Toledo International	$4.03B	7.52	$869.19M	$44.43	34.02
Bio-Rad Laboratories	$2.58B	3.78	$759.90M	$8.25	44.25

Mettler-Toledo International has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

95.1% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are owned by institutional investors. 0.7% of Mettler-Toledo International shares are owned by insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Mettler-Toledo International has a net margin of 21.91% compared to Bio-Rad Laboratories' net margin of 8.59%. Bio-Rad Laboratories' return on equity of 3.54% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mettler-Toledo International	21.91%	-1,212.14%	25.11%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

Mettler-Toledo International currently has a consensus price target of $1,446.36, indicating a potential downside of 4.32%. Given Mettler-Toledo International's stronger consensus rating and higher probable upside, analysts plainly believe Mettler-Toledo International is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mettler-Toledo International	1 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.31
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Mettler-Toledo International had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 6 mentions for Mettler-Toledo International and 0 mentions for Bio-Rad Laboratories. Mettler-Toledo International's average media sentiment score of 0.62 beat Bio-Rad Laboratories' score of 0.00 indicating that Mettler-Toledo International is being referred to more favorably in the media.

Company	Overall Sentiment
Mettler-Toledo International	Positive
Bio-Rad Laboratories	Neutral

Summary

Mettler-Toledo International beats Bio-Rad Laboratories on 13 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Medpace?

Medpace (NASDAQ:MEDP) and Bio-Rad Laboratories (NYSE:BIO.B) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

78.0% of Medpace shares are held by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bio-Rad Laboratories has higher revenue and earnings than Medpace. Medpace is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.83	$451.12M	$17.06	36.28
Bio-Rad Laboratories	$2.58B	3.78	$759.90M	$8.25	44.25

Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Medpace has a net margin of 17.67% compared to Bio-Rad Laboratories' net margin of 8.59%. Medpace's return on equity of 110.15% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

In the previous week, Medpace had 23 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 23 mentions for Medpace and 0 mentions for Bio-Rad Laboratories. Medpace's average media sentiment score of 0.54 beat Bio-Rad Laboratories' score of 0.00 indicating that Medpace is being referred to more favorably in the media.

Company	Overall Sentiment
Medpace	Positive
Bio-Rad Laboratories	Neutral

Medpace currently has a consensus price target of $595.20, suggesting a potential downside of 3.83%. Given Medpace's stronger consensus rating and higher possible upside, research analysts plainly believe Medpace is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Medpace beats Bio-Rad Laboratories on 12 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Revvity?

Bio-Rad Laboratories (NYSE:BIO.B) and Revvity (NYSE:RVTY) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

In the previous week, Revvity had 18 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 18 mentions for Revvity and 0 mentions for Bio-Rad Laboratories. Revvity's average media sentiment score of 0.49 beat Bio-Rad Laboratories' score of 0.00 indicating that Revvity is being referred to more favorably in the news media.

Company	Overall Sentiment
Bio-Rad Laboratories	Neutral
Revvity	Neutral

0.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 86.7% of Revvity shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 0.9% of Revvity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Bio-Rad Laboratories has higher earnings, but lower revenue than Revvity. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	3.78	$759.90M	$8.25	44.25
Revvity	$2.86B	5.89	$241.20M	$2.10	71.83

Revvity has a consensus target price of $116.57, suggesting a potential downside of 22.72%. Given Revvity's stronger consensus rating and higher probable upside, analysts clearly believe Revvity is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Revvity	0 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Bio-Rad Laboratories has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Revvity has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Bio-Rad Laboratories has a net margin of 8.59% compared to Revvity's net margin of 8.16%. Revvity's return on equity of 8.34% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	8.59%	3.54%	2.48%
Revvity	8.16%	8.34%	5.01%

Summary

Revvity beats Bio-Rad Laboratories on 12 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Charles River Laboratories International?

Bio-Rad Laboratories (NYSE:BIO.B) and Charles River Laboratories International (NYSE:CRL) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Charles River Laboratories International has a consensus price target of $287.06, indicating a potential downside of 1.86%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, analysts plainly believe Charles River Laboratories International is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

Bio-Rad Laboratories has a net margin of 8.59% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	8.59%	3.54%	2.48%
Charles River Laboratories International	-5.96%	15.75%	6.51%

In the previous week, Charles River Laboratories International had 20 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 20 mentions for Charles River Laboratories International and 0 mentions for Bio-Rad Laboratories. Charles River Laboratories International's average media sentiment score of 0.61 beat Bio-Rad Laboratories' score of 0.00 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Overall Sentiment
Bio-Rad Laboratories	Neutral
Charles River Laboratories International	Positive

Bio-Rad Laboratories has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Bio-Rad Laboratories has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	3.78	$759.90M	$8.25	44.25
Charles River Laboratories International	$4.02B	3.48	-$144.34M	-$4.85	N/A

0.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Charles River Laboratories International beats Bio-Rad Laboratories on 10 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Icon?

Bio-Rad Laboratories (NYSE:BIO.B) and Icon (NASDAQ:ICLR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Bio-Rad Laboratories has higher earnings, but lower revenue than Icon. Icon is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	3.78	$759.90M	$8.25	44.25
Icon	$8.25B	1.60	$229.34M	$4.26	40.45

0.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 95.6% of Icon shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 44.0% of Icon shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bio-Rad Laboratories has a net margin of 8.59% compared to Icon's net margin of 3.99%. Icon's return on equity of 8.02% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	8.59%	3.54%	2.48%
Icon	3.99%	8.02%	4.56%

In the previous week, Icon had 5 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 5 mentions for Icon and 0 mentions for Bio-Rad Laboratories. Icon's average media sentiment score of 0.54 beat Bio-Rad Laboratories' score of 0.00 indicating that Icon is being referred to more favorably in the news media.

Company	Overall Sentiment
Bio-Rad Laboratories	Neutral
Icon	Positive

Icon has a consensus target price of $170.07, suggesting a potential downside of 1.31%. Given Icon's stronger consensus rating and higher possible upside, analysts plainly believe Icon is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Icon	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.41

Bio-Rad Laboratories has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Icon has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Summary

Icon beats Bio-Rad Laboratories on 12 of the 17 factors compared between the two stocks.

Get Bio-Rad Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIO.B vs. The Competition

Export

Metric	Bio-Rad Laboratories	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$9.76B	$10.94B	$7.29B	$22.90B
Dividend Yield	N/A	1.45%	2.52%	3.68%
P/E Ratio	44.25	73.84	275.27	28.00
Price / Sales	3.78	108.00	614.36	20.55
Price / Cash	36.43	27.70	79.23	41.86
Price / Book	1.32	6.07	10.44	4.66
Net Income	$759.90M	$56.67B	$3.50B	$1.07B
7 Day Performance	N/A	2.34%	-1.28%	-1.12%
1 Month Performance	N/A	2.53%	-4.69%	-5.14%
1 Year Performance	28.15%	41.07%	15.00%	7.69%

Bio-Rad Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIO.B Bio-Rad Laboratories	N/A	$365.08 flat	N/A	+28.2%	$9.76B	$2.58B	44.25	7,450
MTD Mettler-Toledo International	2.5252 of 5 stars	$1,505.28 -0.9%	$1,446.36 -3.9%	+24.9%	$30.18B	$4.03B	33.90	18,100
MEDP Medpace	2.3971 of 5 stars	$611.63 -1.4%	$595.20 -2.7%	+26.8%	$17.07B	$2.53B	35.85	6,200	Insider Trade
RVTY Revvity	3.1123 of 5 stars	$148.76 -1.3%	$116.57 -21.6%	+81.5%	$16.60B	$2.86B	70.84	11,000	Trending News Insider Trade
CRL Charles River Laboratories International	2.8668 of 5 stars	$292.65 -0.6%	$287.06 -1.9%	+100.8%	$13.97B	$4.02B	N/A	19,700	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BIO.B) was last updated on 9/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Rad Laboratories (BIO.B) Competitors

BIO.B vs. MTD, MEDP, RVTY, CRL, and ICLR

How does Bio-Rad Laboratories compare to Mettler-Toledo International?

Summary

How does Bio-Rad Laboratories compare to Medpace?

Summary

How does Bio-Rad Laboratories compare to Revvity?

Summary

How does Bio-Rad Laboratories compare to Charles River Laboratories International?

Summary

How does Bio-Rad Laboratories compare to Icon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIO.B vs. The Competition

Bio-Rad Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Rad Laboratories (BIO.B) Competitors

BIO.B vs. MTD, MEDP, RVTY, CRL, and ICLR

How does Bio-Rad Laboratories compare to Mettler-Toledo International?

Which has preferable earnings and valuation, MTD or BIO.B?

Which has more risk & volatility, MTD or BIO.B?

Do institutionals and insiders have more ownership in MTD or BIO.B?

Is MTD or BIO.B more profitable?

Do analysts rate MTD or BIO.B?

Does the media prefer MTD or BIO.B?

Summary

How does Bio-Rad Laboratories compare to Medpace?

Do insiders & institutionals hold more shares of MEDP or BIO.B?

Which has higher earnings and valuation, MEDP or BIO.B?

Which has more risk & volatility, MEDP or BIO.B?

Is MEDP or BIO.B more profitable?

Does the media refer more to MEDP or BIO.B?

Do analysts prefer MEDP or BIO.B?

Summary

How does Bio-Rad Laboratories compare to Revvity?

Does the media refer more to BIO.B or RVTY?

Do institutionals and insiders hold more shares of BIO.B or RVTY?

Which has preferable earnings & valuation, BIO.B or RVTY?

Do analysts prefer BIO.B or RVTY?

Which has more risk and volatility, BIO.B or RVTY?

Is BIO.B or RVTY more profitable?

Summary

How does Bio-Rad Laboratories compare to Charles River Laboratories International?

Do analysts recommend BIO.B or CRL?

Is BIO.B or CRL more profitable?

Does the media prefer BIO.B or CRL?

Which has more risk and volatility, BIO.B or CRL?

Which has higher earnings and valuation, BIO.B or CRL?

Do insiders & institutionals have more ownership in BIO.B or CRL?

Summary

How does Bio-Rad Laboratories compare to Icon?

Which has better earnings and valuation, BIO.B or ICLR?

Do institutionals and insiders hold more shares of BIO.B or ICLR?

Is BIO.B or ICLR more profitable?

Does the media refer more to BIO.B or ICLR?

Do analysts prefer BIO.B or ICLR?

Which has more volatility & risk, BIO.B or ICLR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIO.B vs. The Competition

Bio-Rad Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools